MOUNTAIN VIEW, Calif., Nov. 16, 2016 /PRNewswire/ -- Juno Biomedical, Inc. announced today that it has entered into a
Based on over 30 years of research in the cell electrotaxis field, CELLTech(TM) could be the solution for those who are suffering with motor function loss after an ischemic stroke.
"It is very important to us that our device is not only safe and effective in returning motor function to those who are disabled after a stroke, but that it additionally takes into account patient functionality," says Trisha Pfluger, CEO. "This means integrating software that can monitor and optimize the patient's physical improvement while offering features that allow the patient and the patient's caregivers and family to be at the center of her therapy."
Stroke remains the #1 cause of long-term disability in the United States, yet has no safe and effective FDA-approved regenerative treatment, leaving millions of individuals left behind by our current medical model.
Frances Cohen, President of Promenade Software, Inc. said: "We are looking forward to assisting Juno Biomedical in bringing CELLTech(TM) to fruition in a modern, interconnected software system that will help stroke victims in ways previously unavailable."
The software component of CELLTech(TM) adds a new layer of customizations such as real time, feedback-based remote patient monitoring and higher granularity of dose control that is not currently available with traditional drug therapies.
"Our exciting technology has been proven in animal models and is now ready to be tested in humans. Working with Promenade software further enhances the reliability of the data we plan to collect in clinical trials and our ability to optimize patient outcomes in a short amount of time," said Dr. Davit Mrelashvili, Chief Medical Officer, Juno Biomedical, Inc.
The field of medicine is undoubtedly moving to integrate more exponential technologies such as digital health, regenerative therapies and personalized medicine. While designing CELLTech(TM), the team continues to leverage these technologies in a way that will remove previously seen glass-ceilings in medicine.
"This technology has the potential to save a tremendous amount of money by decreasing cost to the patient and insurance companies, while increasing top-line revenue for major stroke hospitals," says Allan Bernstein, MD, Medical Director of Sonoma West Research Institute and Clinical Advisor to Juno Biomedical. "Because of this, we have a clear path to market that not only fills an enormous need, but does so in a way that can reduce the current economic burden that has arisen from current limitations of stroke rehabilitation."
The Juno Biomedical team spent almost a year searching for the right software partner before choosing Promenade. "Promenade Software has a successful track record of developing embedded applications for both wearable and implantable medical technologies, while maintaining the necessary regulatory compliance for FDA submissions," said Mike Bellon, Chief Technology Officer, Juno Biomedical, Inc. "Promenade is the right company to help us bring our much-needed therapy to market for stroke survivors across the globe."
The next step for Juno Biomedical is to translate its therapy to human trials in an upcoming study, projected to begin in 2017.
"We have individuals around the globe contacting us for an opportunity to take part in our upcoming study. If proven successful in clinical trials, patients living with severe disability will have a better option," said CEO Trisha Pfluger. "With more sophisticated technologies available than ever before, these are exciting times for Juno Biomedical and for the field of medicine globally. Most importantly, these are exciting times for those suffering the painful reality of long-term physical disability after stroke."
About Juno Biomedical, Inc. Juno Biomedical was launched in 2014 by scientist, author and inventor Trisha Pfluger with an aim to transform the standard of care for persons with neurological impairment. Founded on the idea that patient care should heal the underlying cause of disease in a patient-centric manner, rather than merely alleviating the symptoms, Juno Biomedical endeavors to integrate technologies such as digital patient monitoring, bioelectric therapy, and tissue regeneration to create an innovative medical device that can heal brain tissue damage. The company is pioneering advances not only in healing, but in personalized, in-home medical care. For further information visit JunoBiomedical.com.
About Promenade Software, Inc. Promenade Software, Inc. offers a full suite of software development, test, and regulatory services for medical and other safety critical systems. The company's highly skilled and experienced engineers design in test, maintainability, and quality to every project they do. Promenade's ready-made R&D and test tools help an entire team get their system to market quickly. For further information visit PromenadeSoftware.com
This press release was issued through 24-7PressRelease.com. For further information, visit http://www.24-7pressrelease.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/juno-biomedical-moving-forward-with-regenerative-stroke-treatment-300363890.html
SOURCE Juno Biomedical, Inc.
Subscribe to our Free Newsletters!
Cachexia refers to severe muscle and fat loss, anorexia and marked weight loss due to an underlying ...
Exotropia or outward eye deviation is a form of squint. Proper evaluation and timely intervention ...
Glaucoma is a group of disorders involving the optic nerve, often associated with a rise in ...View All